The Landscape of Emerging HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecologic Malignancies

Healthcare professionals who care for patients with genitourinary, gastrointestinal, and gynecologic malignancies can gain insights into the most up-to-date advances in and clinical evidence of HER2-targeted antibody–drug conjugates in these cancer types and a better understanding of HER2 alterations and oncogenic mechanisms through certified podcasts and Medical Minutes as well as an expert-written ClinicalThought commentary and downloadable slides.

Share

Program Content

Activities

HER2-Targeted ADCs in Solid Tumors
The Lay of the Land: Overview of Biology of HER2 in Genitourinary, Gastrointestinal, and Gynecologic Malignancies
Podcast Episodes
Congratulations: You achieved a completion on 04/09/2022

Released: April 21, 2025

Expires: April 20, 2026

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.